FDA approves treatment for multi-drug resistant HIV
Lenacapavir, an injection, has been approved by the FDA for multi-drug resistant HIV.
Sep 1, 2023
0
23
The Lancet HIV is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice.
Lenacapavir, an injection, has been approved by the FDA for multi-drug resistant HIV.
Sep 1, 2023
0
23
New research from Boston Medical Center found that providing pragmatic support, specifically rapid access to antiretroviral therapy, pharmacotherapy for opioid use disorder, and strengths-based case management, improved treatment ...
Sep 1, 2023
0
1
A study of more than 50 babies in Africa, Asia, North America and South America has added substantially to evidence that giving antiretroviral therapy (ART) to newborns with HIV within the first days—rather than within ...
Dec 5, 2023
0
5
A new research review to be presented at a pre-congress day for this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2024) will focus on the growing prevalence of HIV in older adults, with—using ...
Mar 27, 2024
0
0
A research project studying how best to implement "back to basics" clinical and laboratory care in public hospitals in three African countries has halved the number of deaths from HIV-linked meningitis. The results are reported ...
Oct 5, 2023
0
16
A drug which reduces the risk of HIV is "extremely effective," a new study has affirmed as experts called for the drug to be used more widely.
Nov 30, 2023
0
1
For neonates with in utero HIV-1, very early antiretroviral therapy (ART) can achieve sustained virological suppression, according to a study published online Dec. 4 in The Lancet HIV.
Dec 12, 2023
0
0